SHP2 expression was not associated with clinical stage in laryngeal carcinoma (OR: 2.75; 95% CI, 0.14–55.17; P = 0.52), pancreatic carcinoma (OR: 1.45; 95% CI, 0.58–3.62; P = 0.43), gastric carcinoma (OR: 1.23; 95% CI, 0.85–1.78; P = 0.27), esophagus carcinoma (OR: 0.98; 95% CI, 0.4–2.39; P-0.97), colorectal carcinoma (OR: 0.84; 95% CI, 0.48–1.45; P = 0.53) and thyroid carcinoma (OR: 0.69; 95% CI, 0.38–1.26; P = 0.23) (Fig 5). This evidence concerns the gene PTPN11 and gastric carcinoma.